Novel Targeted Therapies for Blood Cancer
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: closed (17 November 2023) | Viewed by 163
Special Issue Editor
Interests: targeted cancer therapy; tyrosine kinase inhibitors; small molecule inhibitors; apoptosis; monoclonal antibodies; immunomodulators; leukemia; lymphoma; acquired drug resistance; intracellular signaling
Special Issue Information
Dear Colleagues,
Cancer is one of the leading causes of death worldwide. Blood-related cancers are types of cancers that affect blood cells. The most frequent types of blood cancers are leukemia, lymphoma, and myeloma. Various factors can induce DNA changes, leading to the uncontrolled proliferation of mostly undifferentiated blood cells. Genetic, mutagenesis factors in foods and environment, radiations, and defects in the immune system are the most important factors that lead to abnormal behaviors of normal blood cells leading to cancer.
Chemotherapy, radiation, and surgery are usually the first choices for cancer treatment and are widely used in the treatment of cancer. Despite the improvements in patient health quality, the effectiveness of conventional treatments is compromised by several disadvantages. Therefore, new effective treatments focusing on removing malignant cells and minimizing side effects are of great importance. Targeted therapies or personalized medicine are new types of emerging treatments. Several reagents and methods have been improved during recent decades. Chemically synthesized or natural small molecule inhibitors (SMIs), monoclonal antibodies, immunomodulatory reagents, siRNAs, and synthetic peptides are among the reagents that specifically target tumor cells with fewer side effects on normal cells. Currently, several targeted therapy drugs have been approved by FDA for cancer treatment. However, cancer remains an incurable disease and needs special attention from authorities and scientists to recognize the obstacles in front of cancer treatment that remain to be solved.
The current Special Issue therefore encompasses new research articles and timely reviews on new targeted therapy reagents and methods for targeting various types of blood cancers.
You may choose our Joint Special Issue in Cancers.
Dr. Mohammad Hojjat-Farsangi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
